Disease modeling and pharmacological rescue of autosomal dominant Retinitis Pigmentosa associated with *RHO* copy number variation

Sangeetha Kandoi[1,2], Cassandra Martinez[1,2], Kevin Xu Chen[2], Brian C. Mansfield[3], Jacque L. Duncan[1], Deepak A. Lamba[1,2]

[1]Department of Ophthalmology, University of California San Francisco, CA, USA
[2]Eli and Edythe Broad Center of Regeneration Medicine & Stem Cell Research, University of California San Francisco, CA, USA
[3]Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD USA.

Corresponding Author: Deepak A. Lamba. 35 Medical Center Way, IRM, San Francisco CA 94143. Email: deepak.lamba@ucsf.edu

Funding information: NEI R01 EY032197 (DAL), U24 EY029891 (DAL and JLD), UCSF Vision Core NIH/NEI P30 EY002162, Foundation Fighting Blindness (DAL), All May See Foundation post-doctoral fellowship (SK), and an unrestricted grant from Research to Prevent Blindness, New York, NY

Commercial relationships disclosures:
Sangeetha Kandoi - None
Cassandra Martinez - None
Kevin Xu Chen - None
Brian C. Mansfield - None
Jacque L. Duncan - None
Deepak A. Lamba - None

Abstract

Retinitis pigmentosa (RP), a heterogenous group of inherited retinal disorder causes slow progressive vision loss with no effective treatments available. Mutations in the rhodopsin gene (*RHO*), account for ~40% cases of autosomal dominant RP (adRP). In this study, we describe the disease characteristics of the first ever reported mono-allelic copy number variation (CNV) in *RHO* as a novel cause of adRP. We (1) show advanced retinal degeneration in a male patient (~age in years, 60s) harboring four transcriptionally active intact copies of rhodopsin, (2) recapitulate the clinical phenotypes using retinal organoids, and (3) assess the utilization of a small molecule, Photoregulin3 (PR3), as a clinically viable strategy to target and modify disease progression in RP patients associated with *RHO*-CNV. Patient retinal organoids showed outer segment developmental defects (microscopy), increased *RHO* mRNA levels (qRT-PCR and bulk RNA-sequencing), along with elevated expression and mislocalization of rhodopsin protein (RHO) within the cell body of rod photoreceptors (western blotting and immunohistochemistry). Lastly, by targeting the upstream regulator of *RHO*, *NR2E3*, we effectively altered *RHO* expression, leading to the partial rescue of RHO protein localization from the soma to the inner/outer segments of rod photoreceptors and providing a proof-of-principle for personalized medicine. Taken together, this study supports the clinical data indicating that adRP due to rhodopsin CNV develops due to a dominant negative gain of function.

Introduction

Retinitis pigmentosa (RP) is a genetically heterogenous group of rod-cone photoreceptor degenerative diseases that are unified by common clinical features characterized by progressive vision loss, commonly starting as night blindness(O'Neal and Luther 2022). RP affects roughly 1 in 3000-5000 individuals and is inherited as an autosomal recessive, autosomal dominant (ad) or X-linked disease(Chizzolini et al. 2011). adRP can be caused by mutations in at least 24 different known genes("RetNet: Summaries" n.d.) and mutations in rhodopsin gene (*RHO*) are the most common genetic cause. Mutation in the *RHO* was the first identified cause of RP with a single-base substitution at codon 23 (P23H) subsequently leading to protein misfolding and triggering the death of the rod photoreceptors(Dryja et al. 1990). *RHO* is located on the long arm of chromosome 3 (3q22.1) and drives the expression of a 348 amino-acid G protein-coupled receptor (GPCR) with seven transmembrane domains, a luminal N terminus, and a cytoplasmic C terminus. Morphologically, the rhodopsin protein (RHO) is localized in the disc membrane of the rod photoreceptor outer segments. Currently >150 different rhodopsin mutations have been identified, all contributing through multiple mechanisms with each having distinct consequences on the protein structure and function(Athanasiou et al. 2018). Based on the experimentally studied biochemical and cellular characteristics, several mechanisms have been linked with *RHO*-mutation associated photoreceptor degenerations including protein misfolding, endoplasmic reticulum (ER) retention and instability, glycosylation defects, post Golgi trafficking and outer segment targeting, dimerization deficiency, altered post-translational modifications and reduced stability, disrupted vesicular trafficking and endocytosis, impaired protein trafficking all leading to constitutive phototransduction activation or altered transducin interactions(Newton and Megaw 2020).

Very recently, we reported copy number variations (CNV) in *RHO* as a novel
cause of adRP(Duncan et al. 2019). The current study presents a unique opportunity to
better understand the pathogenic effects of two extra copies of intact wild-type *RHO* on
a single allele at 3q22.1 in a male patient (~age in 60s) diagnosed with adRP.
Transgenic mice overexpressing wild-type *Rho* have previously demonstrated
photoreceptor degeneration, however the precise mechanism of degeneration is still
unclear(Olsson et al. 1992). Although mice have similar genetics to humans, the
distribution, subtypes, quantity of retinal cells (especially photoreceptor cells), and the
developmental timeline of the retina, differs greatly(Volland et al. 2015). Therefore,
access to human cells and tissues *vis-à-vis* the retinal organoid model provides a
reliable, translational, and clinically relevant system to gain insights into the pathogenic
effects of excessive rhodopsin in photoreceptors. Induced pluripotent stem cell (iPSC)-
based models have been used to model several retinal degenerations such as Retinitis
Pigmentosa (Tucker et al. 2013; Giacalone et al. 2019), Usher's syndrome (Dulla et al.
2021), Leber congenital amaurosis (LCA) (Parfitt et al. 2016; Kruczek et al. 2021) and a
recent study on *CRX*-associated LCA7(Chirco et al. 2021). This report aimed to unravel
the pathogenesis of late-onset *RHO*-CNV retinal disease using retinal organoids.
Patient-specific retinal organoids serves as a versatile tool for testing various
therapeutic interventions including small molecules which aims at modulating the
pathways(Moore, Skowronska⬚Krawczyk, and Chao 2020; Liu et al. 2021).   Small
molecule-based targeted therapeutics have the potential to cross the blood-brain barrier
when administered systemically and can be therapeutically titrated. Amongst these,
nuclear receptors are important targets as they have druggable ligand-binding sites.
Approximately 15% of approved drugs, target at least 48 members of human nuclear
receptors superfamily, and 10 amongst these are orphan(Zhao, Zhou, and Gustafsson
2019). Numerous orphan nuclear receptors are expressed in the retina. Nuclear
receptor subfamily 2 group E member 3 (*NR2E3*), orphan nuclear receptor in
photoreceptors, is a direct target of neural retina leucine zipper (*NRL*), the main rod-
specifying gene(Kobayashi et al. 1999). It is expressed very early in post-mitotic rods
and coactivates the transcription of rod-specific genes including *RHO*, *CRX* and
NRL(Bumsted O'Brien et al. 2004; Cheng et al. 2004; Mitton et al. 2000). Recent studies
have identified photoregulins (PR), small molecules that target *NR2E3* and can modify
disease progression in some mouse models of rod photoreceptor mutation-associated
RP (Nakamura et al. 2016, 2017). We tested the hypothesis that PR targeting *NR2E3*
can mitigate the deleterious effects of the *RHO*-CNVs using *in vitro* patient-specific
retinal organoids. Overall, we demonstrated the establishment of a human retinal
organoid model of *RHO*-CNV associated with adRP to gain critical insights into the
pathogenesis of human disease and to provide an important screening tool for the
development of potential novel therapies.
130
Results
***RHO*-CNV patient presented clinical characteristics of adRP.**
The clinical and ERG data of a patient and one healthy first-degree relative of the
patients is included (Table 1). Complete ophthalmological examination revealed
features of RP (Hirji 2023) including bone spicule-like pigmentation changes, optic disc
pallor and attenuation of retinal blood vessels (**Figure 1A, Supplementary Figure 1A**),

with outer retinal atrophy due to the loss of the photoreceptor layers, sparing the central
foveal region (**Figure 1B**). Genetic testing of the proband by next-generation
sequencing (NGS) showed a complex duplication-rearrangement of chromosome 3q22,
which encompassed the entire *RHO* coding sequence, 5' and 3' regulatory regions and
flanking genes. The rearrangement consisted of a 48 kb triplicated region embedded
within a 188 kb duplication, resulting in three apparently intact *RHO* genes on one
chromosome and a fourth, unaltered *RHO* gene on the homologous chromosome. Each
of the three intact copies were flanked by *H1FOO*, *IFT122*, *EFCAB12* and *MBD4*,
suggesting a duplication-inverted-and triplication-duplication event, in which the
triplicated segment is inverted and located between correctly oriented genomic
segments (**Figure 1C**). No other additional causative variants of inherited retinal
degeneration candidate genes were identified. Whole genome sequencing supported
the rearrangement and extra copies of *RHO* which were identified by NGS. The *RHO*
copy number variants were not detected in the unaffected daughter of the patient.
Clinically collected four-generation pedigree data of the family (*data not shown*)
included two male family members affected with RP, indicating male-male transmission,
consistent with an autosomal dominant inheritance. The proband's affected father was
not examined as he was deceased, but he had been diagnosed clinically with RP. The
clinical findings were consistent with the hypothesis that copy number variation in the
wild-type rhodopsin gene causes adRP.
157
***RHO*-CNV retinal organoids exhibit photoreceptor maturation defects**.
To assess the effects of *RHO*-CNV in human retinal organoids, we initially
reprogrammed the peripheral blood mononuclear cells (PBMCs) from one patient with
four copies of *RHO* (RM) as well as the corresponding familial control (RC) into iPSCs
(**Supplementary Figure 2A-B**). The iPSC lines had the colony morphology of tightly
packed cells with a high nucleus-to-cytoplasm ratio, a well-defined border typical of
stem cells, and expression of pluripotent markers (**Supplementary Figure 2C-D**). We
then differentiated the patient and control iPSC lines into retinal organoids by following
our previously published protocols(Bachu et al. 2022; Arthur et al. 2022), as per the
differentiation timeline depicted in **Figure 2A** . Retinal organoids from the *RHO*-CNV
patient and the control displayed well-defined neuroepithelial lamination, indicating the
alignment of photoreceptors on the apical surface of the organoids and a dark central
basal region consisting of ganglion cells by phase contrast microscopy (**Supplementary
Figure 2E**). Notably, there were no clear visible anatomical changes in apical-basal
retinal cell type distribution during the early differentiation timeframe, when the cone and
rod photoreceptors are usually born in 45-50-days-old and 90-120-days-old human
retinal organoids, respectively (data not shown). Over the prolonged differentiation
culture timeframe (>180 days), the control (RC) retinal organoids displayed hair-like
protrusions which were presumptive inner and outer segments at the apical side of the
retinal organoids, a critical event indicating start of photoreceptor maturation. In
contrast, to control organoids, all the patient (RM) retinal organoids showed short initial
hair-like protrusions that did not elongate over the extended culture time as far out as
300 days in culture (**Figure 2B**). We further examined the fine structure of
photoreceptors in the *RHO*-CNV organoids using transmission electron microscopy
(**Figure 2C**). Upon assessing the 300-day-old organoids, we observed that while the

patient organoids developed connecting cilium and inner segments like the control
organoids, they failed to develop outer segments, validating the morphological defects
observed by phase-contrast microscopy. Taken together, these morphological changes
suggest that iPSC-retinal organoids from the patient with *RHO*-CNV demonstrated
features consistent with degenerative phenotypes associated to adRP.
188
RHO-CNV retinal organoids revealed conspicuous defects in rod
phototransduction and ciliary transcripts.
Control and patient retinal organoids were analyzed at two developmental
stages: at rod photoreceptor birth (D120), and at rod maturation (D300). For each
sample, qRT-PCR was carried out by utilizing primers designed to nine key genes that
regulate the development and maturation of rod photoreceptors. mRNA levels were
analyzed for the expression of genes specific for early pan photoreceptor (*OTX2, CRX,*
RCVRN), early rod photoreceptors (*NRL, NR2E3*), rod-specific phototransduction
(*PDE6B, SAG, RHO*) and ciliary (*IFT122*) genes (**Supplementary Table 4**). To
equilibrate the data to equivalent the number of photoreceptors in organoids, we
compared the targeted photoreceptor gene expression in RC and RM by normalizing to
CRX, a ubiquitously expressing photoreceptor gene maintained from development to
adulthood(Yamamoto et al. 2020). The expression of all the target genes were detected
at each time point (D120 and D300) in the retinal organoids (**Figure 3A**). Pan-
photoreceptor and early rod marker genes showed similar expression levels with no
noticeable variations in RC and RM organoids. In contrast, the phototransduction and
ciliary genes were expressed at a higher level in the patient than in control organoids.
More relevant to the current study, there was a significant ~3 $\log_2$ fold change (log2FC)
increases in the *RHO* levels at D120 and D300 in the patient organoids. We also
observed a small ~1 log2FC, statistically significant increase in rod arrestin (*SAG*) at
D300. Relatedly, a small ~1 log2FC, non-statistical increases was observed in *IFT122,*
a gene reported to be triplicated in NGS along with *RHO*.
To advance a better molecular understanding on detailed genomic expression
and gene regulatory networks, we performed bulk-RNA sequencing on 300-days-old
retinal organoids (n=3 independent biological replicates). Patient retinal organoids
demonstrated upregulated transcriptomic levels of *RHO* (~3 log2FC) and *SAG* (~2
log2FC), comparable to the qRT-PCR data (**Figure 3B**). Additionally, we also observed
increased expression in other outer segment genes including *PRPH*, visual cycle genes
RDH8 and *HCN1*, and a synaptic gene which includes *PTPRT* in patient relative to
control organoids (**Figure 3B**). Following the Gene Ontology enrichment analysis
(EnrichGO) of significantly differentially up-regulated genes, we confirmed differential
increases in phototransduction cascades including the visual/light perception and
membrane potential/Ca+ signaling pathways in patient organoids. Additionally,
increases in genes associated with the synaptic signaling pathway were also detected,
suggestive of photoreceptor dysfunction (**Figure 3C**). Pathway enrichment analysis of
significantly differentially expressed genes for cellular components category pointed to
perturbation in pathways associated with defects in glycosylation especially N-linked
glycosylation as well as ER and Golgi transport (**Figure 3D, Table 2**), highlighting
potential pathophysiology indicative mechanisms of RHO-CNV associated RP. Although
glycosylation is not required for the rhodopsin biosynthesis, N-linked glycosylation (at

N2 and N15), a post-translational modification, is a necessary step for interacting with
chaperones during ER transport. This is also an essential step towards incorporation of
the heptahelical G-protein coupled receptor rhodopsin in the rod outer segments. Thus,
RNAseq data suggests that the defects in rhodopsin glycosylation possibly decreased
the ability of rhodopsin to exit ER, and leading to an adRP phenotype (Tam and Moritz
2009; C. H. Sung and Tai 1999).

RHO-CNV retinal organoids displayed mis-localized and elevated Rhodopsin
protein levels.
Immunofluorescence staining on the cross sections of control and the patient
retinal organoids was examined for the spatial location of the photoreceptors at three
time points (D120, D200, D300). Pan-photoreceptor precursor and progenitor proteins
(OTX2, CRX), and rod specific proteins (NR2E3) were expressed in the apical layer of
the organoids in a similar pattern both in the control and patient with no observable loss
of photoreceptors (**Supplementary Figure 3A-C**). These results corroborated our gene
expression and transcriptomics data (**Figure 3A-B**) indicating no defects in rod
biogenesis in the patient organoids. As the organoids began to mature, the distribution
of RHO protein was observed in the outer segments of control organoids starting at
D200, earliest timepoint for detection in human retinal organoids using our
differentiation protocol. Compared to the control, the patient organoid had mis-localized
RHO protein accumulating in the photoreceptor cell soma, at all analyzed time-points
(D200, D260 and D300) (**Figure 4A**). Co-staining with NR2E3, a rod-specific marker,
confirmed mislocalized RHO expression in the rod photoreceptor soma within patient
organoids (**Supplementary Figure 3D**). Additionally, we observed an increase in the
expression and localization of rod-specific phototransduction protein, SAG, in patient
retinal organoids (**Figure 4B**).
Patient retinal organoid homogenates displayed a significant 16-fold and 9-fold
higher fractions of ~40 kDa monomer and ~80 kDa dimer rhodopsin content
respectively in patient organoids relative to controls despite loading equal amounts of
protein lysates by western blot (**Figure 4C-C''**). A significant 1.5-fold increase in ~48
kDa SAG protein, a rhodopsin interacting protein was also observed (**Figure 4D-D'**).
These findings suggest that RHO-CNV actively translated the excessive rhodopsin
protein which did not undergo the post-translational modifications that are necessary for
the packaging and transport of rhodopsin to the rod outer segments, ultimately leading
to rod photoreceptor dysfunction and potentially death in the patient.

PR3 treatment attenuates RHO expression and partially rescues RHO trafficking
in RHO-CNV retinal organoids.
Since, the excess RHO protein generation due to the extra RHO copies is likely
not being processed appropriately, we aimed to test potential therapies that may reduce
RHO protein levels in rods. We targeted orphan nuclear receptor, NR2E3, using a small
molecule to assess its effect on RHO regulation and expression in the human patient
organoid model (**Figure 5A**). A small molecule drug, PR3, targeted to NR2E3, has
been previously described to regulate the rod gene expression in Rho[P23H] mice,
suggesting its potential for the use in the treatment of RP (Nakamura et al. 2017). We
treated 300-days-old, RHO-CNV patient retinal organoids with PR3 for one week and

assessed the effects on *RHO* mRNA expression and protein localization. Immunofluorescence staining of PR3-treated organoids displayed a partial rescue of RHO localization with optimal trafficking observed in the 0.25 µM PR3-treated organoids (**Figure 5B**). None of the organoids showed any evidence of toxicity post-treatment. PR3 drove a significant downregulation of *RHO* in a dose-dependent manner (0.1-0.5 µM). Following qRT-PCR analysis, we observed a 2-to-5 log2FC decrease in *RHO* expression, along with smaller decreases in other rod-specific genes such as *NR2E3*, *GNAT1 and PDE6B* (**Figure 5C**). We did not see any significant effects of PR3 on blue-, green- and red-cone opsin genes (**Supplementary Figure 4**). We further compared the *RHO* expression of PR3-treated patient organoids with control (RC) organoids. *RHO* expression levels in the patient organoids treated with 0.1 and 0.25 µM PR3 resembled control organoids, while 0.5 µM PR3 resulted in significantly decreased *RHO* expression compared to control organoid levels (**Figure 5D**).

We further carried out bulk RNA-sequencing analysis to comprehensively characterize three different groups of organoids, 0.25 µM PR3-treated and vehicle-treated patient organoids and control (RC) organoids from three independent differentiation experiments. Consistent with the qRT-PCR gene expression analysis, the results showed a significant downregulation in *RHO* and other rod phototransduction genes including *SAG* and *GNAT1* (**Figure 6A**). Additionally, we confirmed that PR3 did not have any adverse effects on cone opsin transcripts. Principal component analysis (PCA) and normalized read counts analysis of sequenced data for rod (*RHO, SAG, GNAT1, NR2E3*) and other genes demonstrated that the PR3-treated organoids were more alike to control organoids compared to vehicle treated patient organoids (**Figure 6B-C, Supplementary Figure 5B**). Upon KEGG analysis of differentially expressed genes associated with the rod phototransduction pathway from the three different groups of organoids, we observed that several rod pathway components which were upregulated in patient organoids were potentially salvaged following PR3 treatment (**Figure 6D**). EnrichGO analysis of significantly downregulated genes in visual perception/phototransduction pathways confirmed the specific activity of PR3 in retina (**Figure 6E**) while analysis for significantly upregulated genes showed changes in cilium organization, axoneme assembly, ER to Golgi transport and glycosylation, all of which are critical to outer segment formation and protein trafficking (**Figure 6F, Supplementary Figure 5A-B**) suggestive of recovery in rod photoreceptor maturation. Thus, the data presented strongly suggests that PR3, a *NR2E3* modulator, could potentially rescue rod photoreceptor homeostasis in *RHO*-CNV patients.

Discussion

To our knowledge, there have been no previous reports of RP associated with multiple copies of wild-type *RHO* in humans. However, retinal degeneration phenotypes have been reported in mice bearing extra copies of *Rho* and showed that even a 10-30% increase in rhodopsin expression resulted in slow degeneration, while a 3-5-fold increase caused severe and rapid photoreceptor loss (Olsson et al. 1992). More recent studies show that the retinal degeneration phenotype correlated closely to the amount of *RHO* overexpression (Tan et al. 2001; Wen et al. 2009). The current study reports the clinical retinal phenotype of a patient with *RHO*-CNV, and photoreceptor abnormalities in iPSC-derived retinal organoids from the patient.

There is an increasing interest in gene augmentation therapeutic strategies for
retinal degeneration patients with biallelic mutations in *RPE65*, since the approval of
Voretigene neparvovec. Although visual outcomes in most treated patients have been
very encouraging with significant improvement in visual field and light
sensitivity(Maguire et al. 2021), there have been some recent reports of progressive
pericentral atrophy(Gange et al. 2022). One potential cause of retinal pigmented
epithelium (RPE) atrophy following *RPE65* gene augmentation could be overexpression
of *RPE65* in the AAV-*RPE65* infected cells, due to the utilization of strong promoters
such as CAG. Furthermore, the current preclinical approaches to target adRP due to
RHO are primarily based on gene therapies, with three competing approaches. One to
knockdown mutant *RHO* by replacing with a wild-type *RHO*; second to merely
overexpress wild-type RHO(Massengill and Lewin 2021) and third to overexpress
NR2E3, the upstream regulator of *RHO*(Li et al. 2021). Overexpression of wild-type
RHO approach could have unintended adverse consequences on photoreceptor
survival if the relationship between RHO expression and rod survival is not clearly
understood. Our current study on *RHO*-CNV associated with adRP raises the
awareness of toxicities and complications that might arise from either of the gene
augmentation therapy approaches.

Our data strongly supports the notion that the RP phenotype in the patient is
likely due to RHO accumulation and mislocalization in the patient's photoreceptors.
Based on studies in animal models, *RHO* mutations could lead to death of rod
photoreceptors by several mechanisms, including: (a) overwhelming the transport
machinery, thereby mislocalizing and driving cell dysfunction and death, as observed
with Q344R/P/ter *RHO* mutations in mice(C. H. Sung et al. 1994); (b) reducing the
supply of phototransduction deactivating proteins for chromophore-attached RHO,
leading to constitutive activation and degeneration, as proposed in some forms of *RHO*
mutations such as G90D and T94I(Dizhoor et al. 2008); (c) reducing RHO glycosylation
in the Golgi leading to RHO instability and photoreceptor degeneration, as in T17M
mutation(Murray et al. 2015), or by (d) RHO misfolding, driving ER stress/unfolded
protein response (UPR)(Olsson et al. 1992; Chiang et al. 2015). Based on the RNAseq
data in our current study, it is likely that RHO overexpression overloads the rod ER
significantly reducing the efficiency of RHO glycosylation. Previous studies have shown
that RHO undergoes N-linked glycosylation at two distinct sites, Asn-2 and Asn-15. This
glycosylation is believed to be critical for protein folding through interactions with
chaperones as well as for the transport of rhodopsin to the outer segments.
Interestingly, studies in *Xenopus* suggest that this glycosylation is also responsible for
nascent disc assembly(Murray, Fliesler, and Al□Ubaidi 2009). Additionally, we
specifically analyzed the ER stress-UPR pathway in the patient organoids and did not
detect any differences compared to control (*data not shown*).

Nuclear receptors are ideal therapeutic targets because their activities can be
readily induced or repressed with small molecules. This allows for fine tuning of the
biological functions of the receptor to alter disease pathogenesis. A few drugs targeting
these receptors are already in the clinic (Dhiman, Bolt, and White 2018). It is interesting
that targeting a reduction in wild-type RHO expression has also been proposed as a
pan-RP therapy. Several groups have explored reduction in the expression of RHO as
even a little decrease can slow RP progression(Lewin et al. 1998). The photoregulin

group of compounds identified through a screen to target the *NR2E3* orphan nuclear receptor were shown to repress rhodopsin expression with minor effects on cone opsins in mice (Nakamura et al. 2016). Additionally, upon delivery to mice by intra-peritoneal injection, PR3 has been found to be safe and effective in mitigating retinal degeneration, and improving visual function in the P23H rhodopsin mouse model(Nakamura et al. 2017), suggesting photoregulins an attractive preclinical candidates to treat humans with *RHO*-related adRP. Since excessive *RHO* leads to adRP, a tight regulation of *RHO* may be necessary to treat photoreceptor degeneration. In our studies, PR3 had a robust effect on rhodopsin expression with no effects on cone opsins. In conclusion, we have established a disease-in-a-dish model for *RHO*-CNV associated adRP and a potential therapeutic option for managing the devastating outcomes of the disorder.

Conclusion

To our knowledge, this is the first reported study characterizing the *RHO*-CNV, a novel cause of adRP. This case of CNV has expanded the profile of highly mutated *RHO* and by correlating the clinical behavior to disease modeling using retinal organoids. We have used the organoid model for targeted drug testing with PR3, small molecule inhibitor of *NR2E3*. Taken together, the results of this study demonstrate that *RHO* expression requires precise control for rod photoreceptor functioning and maintenance.

Methods
Clinical and Molecular Diagnosis

Both the proband (Male patient, ~age in years, 60s) and his unaffected daughter (~age in years, 30s) provided written informed consent, which was approved by the UCSF Institutional Review Board (IRB # 18-26409) and adhered to the tenets set forth in the Declaration of Helsinki. The participants gave consent to participate in the current study and have the results of this research work published. The proband (unidentified Lab ID # RM) and his asymptomatic daughter (unidentified Lab ID # RM) were examined at the University of California San Francisco (UCSF, CA, USA) including the pedigree data collection, clinical examination, and genetic diagnosis. Retinal examination included visual acuity testing, fundus photography, spectral domain optical coherence tomography (SD-OCT), full-field electrophysiological testing (ERG). For genetic diagnosis of *RHO*-CNV, peripheral blood (PB) samples collected from the proband and the unaffected daughter of the proband were screened by targeted Next Generation Sequencing (NGS) using a 266-gene retinal dystrophy panel and whole genome sequencing (Blueprint Genetics, USA).

Generating iPSC lines.

Peripheral blood samples collected from the human subjects (unidentified Lab ID # RC and RM) were reprogrammed into iPSCs as per the schematic outlined in **Supplementary Figure 2A**. Blood samples were processed by density-gradient centrifugation using Ficoll-paque™ PLUS (17-1440-02, GE Healthcare Biosciences, Sweden) to isolate the peripheral blood mononuclear cells (PBMNCs) (**Supplementary Figure 2B)**. A small fraction of ~1-2 x 10^6 MNCs was cultured in 1-well of a 12-well suspension plate with peripheral blood mononuclear cells (PBMNC) expansion medium

(**Supplementary Table 1**) by changing half media every day. Date of seeding the
PBMC in culture was designated as Day (D) -4. Four days later, ~0.2-0.4 x 10^6 PBMCs
were reprogrammed using CytoTune™-iPS 2.0 Sendai Reprogramming Kit (A16517,
Thermo Fisher Scientific, USA), at 2.5:2.5:1.5 (KOS:c-myc: Klf4) multiplicity of infection.
24h post-transfection on D1, a full media change was done. Two days post transfection
on D3, cells were plated onto 1-2 wells of a Matrigel (354234, Corning, USA, diluted as
1 µg/mL in DMEM/F12)-coated 6-well plate with reprogramming medium
(**Supplementary Table 1**). Half media change was done on every other day from D3
until D6. For all the suspension cultures, medium change was done by centrifugation at
200x *g* for 10 minutes and resuspending the cell pellet with the respective medium and
culturing back into the plates. On D8, cells were transitioned to iPSC medium
(**Supplementary Table 1**) with further media changes done on every other day. About
14-21 days post transfection, colonies with typical characteristics of iPSC morphology
were manually picked. Pure, compact, and tightly packed iPSC clones were split using
Passaging solution (**Supplementary Table 1**) for further expansion, characterization
(**Supplementary Figure 2C-G)**, and retinal organoid differentiation.
429
Retinal Organoid Differentiation.
Retinal organoids were differentiated using one clone from each iPSC lines *via*
the three step embryoid body (EB) approach following our previously published
protocols and as per the schematic depicted in **Figure 3A**(Bachu et al. 2022; Arthur et
al. 2022). Briefly, iPSC colonies were lifted and cultured in 6-well suspension plate.
Small iPSC colonies self-aggregated as EBs within 24h were gradually transitioned to
complete Neural Induction Medium (NIM) (**Supplementary Table 1**) from D0 to D3. On
D6, EBs were treated with 1.5 nM BMP4 (120-05ET, PeproTech, USA). By D7, the EBs
were transferred onto a Matrigel-coated plate with NIM and 1.5 nM BMP4 to facilitate
the adherence of EBs to the plate. Brief exposure of BMP4 in the differentiation process
included the treatment of EBs with 1.5 nM (from D6-D8) to 0.75 nM (D9-D11) and 0.375
nM (D12-14). On D15, BMP4 was completely removed and EBs were fed with just NIM.
From D16 through D30, the adherent EBs were fed Retinal Differentiation Medium
(RDM) (**Supplementary Table 1**) at the intervals of every 2 days. Regions of the plate
displaying clear, shiny borders indicating the retina-like morphology were manually lifted
using a sterile P100 pipette tip. Lifted neural retina was transferred to a 6-well
suspension plates and allowed to self-acquire the 3D organoid configuration within the
next 2 days. From D31, the developing retinal organoids were fed 3D-RDM medium
(**Supplementary Table 1**) along with 1 µM All-trans retinoic acid (R2625, Millipore
Sigma) every 3days until D120. From D120 onwards, organoids were fed with just 3D-
RDM medium without All-trans retinoic acid every 3 days until the completion of the
study. Organoids were periodically assessed for morphological characteristics using
phase contrast microscopy (Olympus IX70) at regular intervals. Various time-points of
rod photoreceptor differentiation and maturation in the retinal organoids were utilized for
phenotypic characterization and drug assessments (**Supplementary Figure 3B**).
455
456 ### *Immunohistochemistry and Imaging.*
457 Retinal organoids and confluent colonies of iPSCs were fixed in 4%
458 paraformaldehyde (PFA) (157-8, Electron Microscopy Sciences, USA) in 1X PBS for 20

minutes. Organoids were cryopreserved in 15% through 30% sucrose (made in 1X PBS), and frozen in 2:1 mixture (20% sucrose: OCT, Sakura, USA). 10 µm sections of retinal organoids were collected on Super frost® Plus microscopic slides (12-550-15, Fisher Scientific, USA) using Leica CM3050 S cryostat. Immunohistochemistry was done as described previously. Organoid sections were pap-pen and PFA-fixed iPSC clones were permeabilized at room temperature for 15 mins with 0.1% Triton® X-100 (0694-1L, VWR Life Science, USA) in 10% Normal Donkey Serum (NDS, S30-100ML, EMD Millipore Corp, USA; made in 1X PBS). Following to that, sections were incubated for 1 hour in 10% NDS. Primary antibodies (**Supplementary Table 3A**) diluted in 10% NDS were added to the slides and incubated overnight (12-18 h) at 4°C. The slides were washed thrice in 1X PBS at 5 mins intervals and further incubated for 1 hour at room temperature with fluorescently conjugated secondary antibodies (**Supplementary Table 3B**) diluted at 1:250 in 10% NDS. Cell nuclei were counter stained with DAPI (1ug/mL, Roche, USA) for 10 minutes. The slides were then washed thrice in 1X PBS at 5 mins interval and cover slipped using Fluoromount G (Electron Microscopy Sciences, USA). Images were acquired using ZEN software on LSM700 confocal microscope (Zeiss, Inc.) and processed by Image J (NIH, USA).

RNA extraction and Quantitative Real-Time PCR (qRT-PCR).

Total RNA was extracted from retinal organoids using RNeasy® Mini Kit (74104, Qiagen, USA) as per the manufacturer's instructions. The quality and purity of the extracted RNA was assessed by NanoDrop One (Thermo Fisher Scientific, USA). cDNA was synthesized using iScript cDNA Synthesis Kit (1708891, Bio-Rad, USA). Real-time qRT-PCR was performed on CFX96 system (Bio-Rad, USA) using iTaq™ Universal SYBR® Green Supermix (64047467, Bio-Rad, USA). Primer sequences used for qRT-PCR is listed in **Supplementary Table 4**. The amplification reactions set were: 95°C for 30 s, 40 cycles at 95°C for 5 s, 60°C for 25 s, 95°C for 5 s and final extension at 95°C for 5 s. The Ct values of the target genes were first normalized to the endogenous control β-actin. The corrected Ct values were then utilized to compare and validate the control and patient retinal organoids. Log_2 fold change in gene expression of all targets were then calculated.

Bulk RNA Sequencing.

The quality control, RNA library preparations and sequencing reactions of the extracted RNA from retinal organoids were performed at Novogene Corporation Inc (CA, USA). FASTQ files received from Novogene following QC were quantified using Salmon package (V 1.9.0) by pseudo-aligning against homo sapiens hg19 genomic assembly in Galaxy(Afgan et al. 2016). Low-counts (<10) were filtered out and batch correction was carried out using Combat package in DEBrowser (v1.24.1) R package (Kucukural et al. 2019). Differential expression analysis was carried out using DESeq2 in DEbrowser. Genes with an adjusted p-value < 0.05 were assigned as differentially expressed. Gene ontology enrichment analysis and KEGG pathway analysis of differentially expressed genes was carried out in DEBrowser and Beavr (Perampalam and Dick 2020)packages. Differential expression analysis and pathway enrichment data have been uploaded as supplementary files (**Table 2**).

Transmission Electron Microscopy (TEM)

Retinal organoids (300-days-old) were washed in 1X PBS three times at 10 mins intervals and fixed with Karnovsky's fixative (4% paraformaldehyde/2% glutaraldehyde in 0.1 M PBS, pH 7.4) overnight at 4°C. For TEM, organoids were washed in 1X PBS and stained in 1% osmium tetroxide (19180, Electron Microscopy Sciences, USA; made in distilled water) for 1 hour at room temperature followed by staining with 2% uranyl acetate (22400, Electron Microscopy Sciences, USA; made in distilled water). After three washes in distilled water, organoids were then dehydrated in a graded series of ice-cold ethanol (50%, 70%, 95% and 100%) for 20 mins each. Organoids were incubated in propylene oxide (00235-1, Polysciences Inc, USA) twice for 5 mins, followed by a 5-mins incubation in 1:1 mix of propylene oxide: Epon 812 (13940, Electron Microscopy Sciences, USA). Organoids were allowed to infiltrate in Epon 812 overnight at room temperature. Next day, the organoids were embedded in PELCO silicone rubber molds (105, Ted Pella Inc, USA) using Epon 812, and polymerized for 48 hours at 60°C. Ultrathin (70 nm) sections were collected and imaged using a Philips Tecnai 10 electron microscope at the VA Medical Center, San Francisco, USA.

Western Blotting.

Retinal organoids were collected and washed in cold 1X PBS twice at 5 mins intervals. Protein was extracted by homogenizing the organoids using hand-held pestle (1415-5390, USA Scientific) in ice-cold RIPA buffer (**See supplementary Table 2A**) with 1% complete™ Protease inhibitor cocktail (11697498001, Roche Diagnostics, GmbH). Lysates were incubated at 4°C for 10 minutes and then centrifuged at 14,000 *xg* for 15 minutes at 4°C. Supernatant was collected and the protein concentration was measured using Pierce™ BCA Protein Assay Kit (23227, Thermo Scientific, USA) as per the manufacturer's instructions. Equal amounts (20 µg) of protein lysates were mixed with 4x Laemmli sample buffer (161-0747, Bio-Rad, USA) and 10% dithiothreitol (DTT, R0861, Thermo Scientific, USA). Samples were resolved on a precast gel (12% Mini-Protean TGX Gels, 456-1044, Bio-Rad, USA) for 20 mins at 70 V until the loading dye entered the resolving layer, then increased to 150 V for 40-60 mins or until the run was completed (**See supplementary Table 2A**). After electrophoresis, the proteins were transferred onto an Immobilon®-FL PVDF membrane (IPFL20200, Merck Millipore, USA) ice-cold transfer buffer (**See supplementary Table 2A**) at 100V for 90 minutes. The blots were blocked with blocking solution for 30 minutes. The blots were incubated overnight at 4°C with primary antibodies diluted in blocking solution (**See supplementary Table 3A for primary antibody details**). Thereafter, blots were washed thrice with TBS-T buffer (10 mins interval each) and incubated for 1 hour at room temperature with host-specific secondary antibodies diluted in blocking solution (**See supplementary Table 3B for secondary antibody details**). The blots were washed another three times with TBS-T buffer (10 mins interval each) and visualized using LiCor Odyssey XF scanner. For quantification of protein expression, the background was subtracted for each band and normalized to internal control band using Image J software. Statistical calculations were performed using multiple technical and five independent biological replicates.

PR3 treatment on Retinal Organoids.

Patient-specific *RHO*-CNV retinal organoids (~300-days-old) were treated with small molecule Photoregulin3 (PR3, SML2299-5MG, Sigma, 5 mM stock made in DMSO) supplemented in 3D-RDM for 1 week by changing medium every other day. Three different concentrations of PR3 utilized in this study were 0.1 µM, 0.25 µM, and 0.5 µM. DMSO was used as a vehicle control. One-week, post-PR3 treatment, retinal organoids were assessed by qRT-PCR, bulk RNA sequencing and imaging experiments.

Statistical Analysis.

All the data were obtained from three independent retinal differentiation experiments. The quantified data values were provided as mean ± SEM. The intergroup differences for all the analysis were determined with the GraphPad Prism v9, using a two-tailed student's t-test or ANOVA. Significant differences are indicated by p values listed in the figures. For imaging studies, at least 3 sections were averaged to account for regional variability in iPSC reprograming and retinal organoid differentiation.

Acknowledgments

We are grateful to the recruited human subjects and families included in this study. We thank members of the Lamba lab for helpful discussions and suggestions. The research presented here is supported by the R01 EY032197, Foundation Fighting Blindness research grant to D.A.L., U24 EY029891 to DAL and JLD. All May See Foundation post-doctoral fellowship to S.K, UCSF Vision Core NIH/NEI P30 EY002162, and unrestricted grant from Research to Prevent Blindness, New York, NY to Dept. of Ophthalmology. We deeply appreciate the help of Yien-Ming Kuo at the UCSF Vision Core and Ivy Hsieh AT VA Medical Center for processing samples for electron microscopy studies. We would also like to thank Suling Wang for drawing all the illustrations included in this paper based on the descriptions given by the authors. Additionally, we would like to acknowledge the contributions of The Foundation Fighting Blindness My Retina Tracker® Genetic Testing Program which identified the *RHO*-CNV in the patient. We deeply appreciate the services given by Blueprint Genetics who undertook the genetic analysis and particularly Miika Mehine and Sari Tuupanen who resolved the complex genetic rearrangement within the *RHO* locus.

Main Figures

Figure 1: **Retinal imaging and next generation sequencing. (A)** Ophthalmological color fundus examination of a patient clinically diagnosed of *RHO*-CNV displaying bone spicule pigmentary changes. **(B)** OCT image showing extensive loss of the outer retinal layers leaving an intact island at the fovea. **(C)** Schematic illustration of NGS using a 266-gene retinal dystrophy panel showing a complex chromosome 3q22 duplication-rearrangement resulting in 48 kb triplicated region embedded within a 188 kb duplication forming three apparently intact *RHO* genes on one allele and a fourth, unaltered *RHO* on the homologous allele. NGS=Next generation sequencing; OCT= Optical coherence tomography.

Figure 2: *RHO*-CNV **disease modeling using iPSC-derived retinal organoids showed morphological defects. (A)** Schematic representation showing the timeline of human retinal differentiation and maturation including the birth and development of rod photoreceptors. **(B)** Phase contrast microscopy images showing long hair-like protrusions (OS) from differentiated photoreceptors (ONL) present at the apical surface of retinal organoids from control (RC) at day 200, 260 and 300 (top). Retinal organoids from patient (RM) showing shorter protrusions which do not extend progressively over long-term culturing indicating maturation defects (bottom). **(C)** Electron microscopy images showing ultra-magnification of distinct OS, IS and CC structures of rod photoreceptors in control organoids and the absence of OS is shown in patient organoids. CC=Connecting cilium; IS=Inner segments; ONL= outer nuclear layer; OS=Outer segments. Scale bar = 50 µm.

Figure 3: **Transcriptomic analysis of** *RHO*-CNV **retinal organoids presented elevated RHO expression. (A)** qRT-PCR analysis shows ~3 Log2FC increased *RHO* mRNA levels in patient (RM) organoids at all time-points of rod differentiation and maturation. No significant change was observed in other photoreceptor genes except for a small ~1 Log2FC increase in rod arrestin (SAG) at D300 time-point. Log2FC=Log 2 Foldchange. Statistical two-way ANOVA analysis with Fisher's LSD test and 95% confidence interval. * = $p < 0.05$, and **** = $p < 0.0001$. Aqua bars, D120; gray bars, D300 **(B)** Volcano plot showing significant differentially expressed genes. Significantly upregulated genes are highlighted in red and significantly downregulated genes are highlighted in blue (adjusted $p < 0.01$). **(C)** Dot plot showing EnrichGO analysis of biological process on the differentially expressed genes. The size of the dot represents number of differentially expressed genes in the pathway and the X-axis represent the ratio over all genes associated with the pathway. Plot shows a defect in rods and phototransduction associated pathways as well as synaptic transmission suggesting rod dysfunction. **(D)** Box plot showing the data from pathway enrichment analysis of cellular component category predominantly highlighting the defect in glycosylation and Golgi/ER modification/transport. Colors in the dot and blot plots represent relative significance (calculated p-values in scale). N=3-4 independent experiments and 12-15 organoids per experiment.

Figure 4: **Rhodopsin protein mislocalization and increased levels in** *RHO*-CNV **retinal organoids. (A)** Immunofluorescence staining of RHO displaying the proper localization (arrowheads) in the outer segments and improper localization (arrowheads) in the cell body of photoreceptors within the control (RC; top) and patient (RM; bottom) organoids respectively at all time-points. **(B)** SAG expression (red) followed a similar trajectory as RHO, with increased labelling in patient organoids (bottom) over control (top). DAPI (blue) labels nuclei. OS=outer segment; ONL=outer nuclear layer. Scale bar = 25 µm. **(C)** Blot probed for RHO and SAG showing increased levels of 40 kDa monomer and 80 kDa dimer, RHO **(C)**, and 48 kDa, SAG **(D)** in patient retinal organoids. β-actin was used as a loading control. Densitometric analysis quantifying the relative intensity of monomeric RHO **(C')**, dimeric RHO **(C'')**, and SAG **(D')** in comparisons to the control. Statistical two-tailed unpaired T-test analysis with 95%

642 confidence level. * = p <0.05, and ** = p <0.01. N=5 independent experiment and 12-15
643 organoids per experiment.
644
645
Figure 5: **Partial rescue of rhodopsin localization and expression levels in PR3
treated *RHO*-CNV retinal organoids. (A)** Cartoon illustration showing gene expression
during the stepwise development and maturation of rod photoreceptors. Small molecule,
PR3 acts on *NR2E3* downregulating the expression of *GNAT1, PDE6B, SAG* and *RHO*.
(B) Immunostaining of ~300-days-old PR3-treated retinal organoid sections from patient
(RM) showing the trafficking of RHO protein (arrowheads) towards outer segments at all
doses of PR3. The most appropriate RHO localization to OS is seen at 0.25 µM PR3
(arrowheads). DAPI (blue) labels nuclei. OS=outer segment; ONL=outer nuclear layer.
Scale bar =25 µm. **(C)** qRT-PCR analysis shows ~2-5 Log2FC decrease in *RHO* mRNA
levels in a dose-dependent manner for PR3 treated-patient (RM) organoids. No
significant change was observed in *NRL*, but a small decrease was observable in
GNAT1, PDE6B and *NR2E3* (one-way ANOVA analysis with Sidak test and 95%
confidence interval). **(D)** qRT-PCR analysis showing a comparison of *RHO* mRNA
levels in PR3-treated patient organoids to control (RC) organoids (unpaired t-test).
Log2FC=Log2 Foldchange. * = p <0.05, ** = p <0.01 and *** = p <0.001. N=3-4
independent experiments and 12-15 organoids per experiment.
662
**Figure 6: RNA sequencing analysis of *RHO*-CNV organoids following PR3
treatment. (A)** Volcano plot showing significant differentially expressed genes following
1 week of PR3 treatment in D300+ patient organoids with cutoffs at p<0.01 and
~1log2FC. **(B)** 3D principal component analysis (PCA) plot showing the tightly clustered
independent biological replicates. Additionally, PR3 treated patient organoids were
spatially closer to control (RC) compared to patient (RM) organoids. **(C)** Normalized
read count plots showing relative expression of *RHO, GNAT1, SAG* and *NR2E3*. **(D)**
KEGG analysis of differentially expressed genes showing dysregulation of key
phototransduction pathway comparing RC with RM organoids and the recovery
following PR3 treatment of RM organoids. Down- and up-regulated genes are indicated
in blue and red respectively. **(E, F)** Box plots showing EnrichGO analysis of differentially
expressed genes that are either downregulated (**E**) or upregulated (**F**) by comparing
PR3 treated to vehicle treated organoids. N=3 independent experiments and 12-15
organoids per experiment.
677
678
679
680
681 **Supplementary Figures:**
682 **Supplementary Figure 1**: ***RHO*-CNV identification. (A)** Fundus photography showing
683 the retina of control (RC) and irregular pigmentation pattern in a patient (RM). All the
684 clinical hallmarks of RP including black-spicule pigmentation, attenuated blood vessel
685 and optic disc pallor seen in patient are indicative of RP.

Supplementary Figure 2: **Patient-specific iPSC reprogramming and retinal organoids. (A)** Timeline depicting the sequence of events for reprogramming the PBMCs to iPSCs *via* Cytotune™ iPS 2.0 Sendai Reprogramming kit. **(B, C)** Representative phase contrast microscopy image of PBMCs and a stably generated iPSC colony. **(D)** Confocal microscopic images of an iPSC colony expressing pluripotent markers, SOX2, OCT3/4, NANOG and a co-localized image of all three pluripotent markers. DAPI labels nuclei. Scale bar = 25 µm. **(E)** Low-power bright-field microscopic images showing full view of a retinal organoid from control (RC) and patient (RM) at different time-points of photoreceptor maturation. Patient organoids showed much shorter and less dense protrusions in comparison to control. Scale bar = 50 µm. iPSC=induced pluripotent stem cells; OS=outer segment; ONL=outer nuclear layer; PBMC=Peripheral blood mononuclear cells.

Supplementary Figure 3: **Rod biogenesis and development in *RHO*-CNV retinal organoids did not differ from control.** Confocal microscopic images of control (RC) and patient (RM) organoids labeling the early pan-photoreceptor markers, OTX2 and CRX; and early rod-specific post-mitotic photoreceptor marker, NR2E3 showing no difference in expression during **(A)** rod biogenesis at D120 **(B)** early rod maturation at D200, and **(C)** late rod maturation at D300. **(E)** Immunolabeling of patient (RM) organoids showing the double staining of rod marker, NR2E3 along with RHO protein displaying the mislocalized expression of RHO within the cell body of patient (RM) at D260. DAPI (blue) labels nuclei. Scale bar = 25 µm.

Supplementary Figure 4: **PR3 treated *RHO*-CNV retinal organoids do not affect cone opsin expression**. **(A)** qRT-PCR analysis shows no effect on cone opsin (*BCO, GCO, LCO*) mRNA levels at all the doses of PR3 treated-patient (RM) retinal organoids. Statistical analysis (ANOVA) revealed no significant differences. N=3 independent experiments and 12-15 organoids per experiment.

Supplementary Figure 5: **Recovery in glycosylation and ER-Golgi transport pathways in PR3-treated *RHO*-CNV organoids. (A)** Box plot showing the data from pathway enrichment analysis of cellular component category of differentially expressed genes following PR3 treatment showing the recovery in the dysregulated glycosylation as well as ER pathways **(B)** Normalized read count plots showing relative expression of *MAN1A2, MIA3, TFG, GBF1, COG3, SEC16B, SEC13, ARF4,* and *ALG12* in control(RC), patient (RM) and PR3-treated organoids. N=3 independent experiments and 12-15 organoids per experiment.

References

Afgan, Enis, Dannon Baker, Marius van den Beek, Daniel Blankenberg, Dave Bouvier, Martin Čech, John Chilton, et al. 2016. "The Galaxy Platform for Accessible, Reproducible and Collaborative Biomedical Analyses: 2016 Update." *Nucleic Acids Research* 44 (W1): W3–10. https://doi.org/10.1093/nar/gkw343.

Arthur, Peggy, Sangeetha Kandoi, Li Sun, Anil Kalvala, Shallu Kutlehria, Santanu
Bhattacharya, Tanmay Kulkarni, et al. 2022. "Biophysical, Molecular and Proteomic
Profiling of Human Retinal Organoid-Derived Exosomes." *Pharmaceutical Research*,
August. https://doi.org/10.1007/s11095-022-03350-7.

Athanasiou, Dimitra, Monica Aguila, James Bellingham, Wenwen Li, Caroline McCulley,
Philip J Reeves, and Michael E Cheetham. 2018. "The Molecular and Cellular Basis
of Rhodopsin Retinitis Pigmentosa Reveals Potential Strategies for Therapy."
Progress in Retinal and Eye Research 62 (January): 1–23.
https://doi.org/10.1016/j.preteyeres.2017.10.002.

Bachu, Vismaya S, Sangeetha Kandoi, Ko Uoon Park, Michael L Kaufman, Michael
Schwanke, Deepak A Lamba, and Joseph A Brzezinski. 2022. "An Enhancer Located
in a Pde6c Intron Drives Transient Expression in the Cone Photoreceptors of
Developing Mouse and Human Retinas." *Developmental Biology* 488 (August): 131–
50. https://doi.org/10.1016/j.ydbio.2022.05.012.

Bumsted O'Brien, Keely M, Hong Cheng, Yibin Jiang, Dorothea Schulte, Anand
Swaroop, and Anita E Hendrickson. 2004. "Expression of Photoreceptor-Specific
Nuclear Receptor NR2E3 in Rod Photoreceptors of Fetal Human Retina."
Investigative Ophthalmology & Visual Science 45 (8): 2807–12.
https://doi.org/10.1167/iovs.03-1317.

Cheng, Hong, Hemant Khanna, Edwin C T Oh, David Hicks, Kenneth P Mitton, and
Anand Swaroop. 2004. "Photoreceptor-Specific Nuclear Receptor NR2E3 Functions
as a Transcriptional Activator in Rod Photoreceptors." *Human Molecular Genetics* 13
(15): 1563–75. https://doi.org/10.1093/hmg/ddh173.

Chiang, Wei-Chieh, Heike Kroeger, Sanae Sakami, Carissa Messah, Douglas
Yasumura, Michael T Matthes, Judith A Coppinger, Krzysztof Palczewski, Matthew M
LaVail, and Jonathan H Lin. 2015. "Robust Endoplasmic Reticulum-Associated
Degradation of Rhodopsin Precedes Retinal Degeneration." *Molecular Neurobiology*
52 (1): 679–95. https://doi.org/10.1007/s12035-014-8881-8.

Chirco, Kathleen R, Shereen Chew, Anthony T Moore, Jacque L Duncan, and Deepak
A Lamba. 2021. "Allele-Specific Gene Editing to Rescue Dominant CRX-Associated
Leber Congenital Amaurosis (LCA7) Phenotypes in a Retinal Organoid Model." *Stem
Cell Reports* 16 (November): 1–13.

Chizzolini, Marzio, Alessandro Galan, Elisabeth Milan, Adolfo Sebastiani, Ciro
Costagliola, and Francesco Parmeggiani. 2011. "Good Epidemiologic Practice in
Retinitis Pigmentosa: From Phenotyping to Biobanking." *Current Genomics* 12 (4):
260–66. https://doi.org/10.2174/138920211795860071.

Dhiman, Vineet K, Michael J Bolt, and Kevin P White. 2018. "Nuclear Receptors in
Cancer - Uncovering New and Evolving Roles through Genomic Analysis." *Nature*
Reviews. Genetics 19 (3): 160–74. https://doi.org/10.1038/nrg.2017.102.

Dizhoor, Alexander M, Michael L Woodruff, Elena V Olshevskaya, Marianne C Cilluffo,
M Carter Cornwall, Paul A Sieving, and Gordon L Fain. 2008. "Night Blindness and
the Mechanism of Constitutive Signaling of Mutant G90D Rhodopsin." *The Journal of*
Neuroscience 28 (45): 11662–72. https://doi.org/10.1523/JNEUROSCI.4006-08.2008.

Dryja, T P, T L McGee, E Reichel, L B Hahn, G S Cowley, D W Yandell, M A Sandberg,
and E L Berson. 1990. "A Point Mutation of the Rhodopsin Gene in One Form of
Retinitis Pigmentosa." *Nature* 343 (6256): 364–66. https://doi.org/10.1038/343364a0.

Dulla, Kalyan, Ralph Slijkerman, Hester C van Diepen, Silvia Albert, Margo Dona,
Wouter Beumer, Janne J Turunen, et al. 2021. "Antisense Oligonucleotide-Based
Treatment of Retinitis Pigmentosa Caused by USH2A Exon 13 Mutations." *Molecular*
Therapy 29 (8): 2441–55. https://doi.org/10.1016/j.ymthe.2021.04.024.

Duncan, Jacque L, Karmen Trzupek, Joan Fisher, Leilla Kenney, Sari Tuupanen, Miika
Mehine, Stephen P Daiger, and Brian Mansfield. 2019. "Multiple Copies of Rhodopsin
as a Novel Cause of Autosomal Dominant Retinitis Pigmentosa." *Investigative*
Ophthalmology & Visual Science 60 (9): 2943–2943.

Gange, William S, Robert A Sisk, Cagri G Besirli, Thomas C Lee, Margaret Havunjian,
Hillary Schwartz, Mark Borchert, et al. 2022. "Perifoveal Chorioretinal Atrophy after
Subretinal Voretigene Neparvovec-Rzyl for RPE65-Mediated Leber Congenital
Amaurosis." *Ophthalmology Retina* 6 (1): 58–64.
https://doi.org/10.1016/j.oret.2021.03.016.

Giacalone, Joseph C, Jeaneen L Andorf, Qihong Zhang, Erin R Burnight, Dalyz Ochoa,
Austin J Reutzel, Malia M Collins, et al. 2019. "Development of a Molecularly Stable
Gene Therapy Vector for the Treatment of RPGR-Associated X-Linked Retinitis
Pigmentosa." *Human Gene Therapy* 30 (8): 967–74.
https://doi.org/10.1089/hum.2018.244.

Hirji, Sitara H. 2023. "Clinical Evaluation of Patients with Retinitis Pigmentosa." *Methods*
in Molecular Biology 2560: 31–39. https://doi.org/10.1007/978-1-0716-2651-1_3.

Kobayashi, M, S Takezawa, K Hara, R T Yu, Y Umesono, K Agata, M Taniwaki, K
Yasuda, and K Umesono. 1999. "Identification of a Photoreceptor Cell-Specific
Nuclear Receptor." *Proceedings of the National Academy of Sciences of the United*
States of America 96 (9): 4814–19. https://doi.org/10.1073/pnas.96.9.4814.

Kruczek, Kamil, Zepeng Qu, James Gentry, Benjamin R Fadl, Linn Gieser, Suja
Hiriyanna, Zachary Batz, et al. 2021. "Gene Therapy of Dominant CRX-Leber

Congenital Amaurosis Using Patient Stem Cell-Derived Retinal Organoids." *Stem Cell*
Reports 16 (2): 252–63. https://doi.org/10.1016/j.stemcr.2020.12.018.

Kucukural, Alper, Onur Yukselen, Deniz M Ozata, Melissa J Moore, and Manuel Garber.
2019. "DEBrowser: Interactive Differential Expression Analysis and Visualization Tool
for Count Data." *BMC Genomics* 20 (1): 6. https://doi.org/10.1186/s12864-018-5362-
x.

Lewin, A S, K A Drenser, W W Hauswirth, S Nishikawa, D Yasumura, J G Flannery, and
M M LaVail. 1998. "Ribozyme Rescue of Photoreceptor Cells in a Transgenic Rat
Model of Autosomal Dominant Retinitis Pigmentosa." *Nature Medicine* 4 (8): 967–71.
https://doi.org/10.1038/nm0898-967.

Liu, Lisa, Lei Yu, Zhichao Li, Wujiao Li, and WeiRen Huang. 2021. "Patient-Derived
Organoid (PDO) Platforms to Facilitate Clinical Decision Making." *Journal of*
Translational Medicine 19 (1): 40. https://doi.org/10.1186/s12967-020-02677-2.

Li, Sujun, Shyamtanu Datta, Emily Brabbit, Zoe Love, Victoria Woytowicz, Kyle Flattery,
Jessica Capri, et al. 2021. "Nr2e3 Is a Genetic Modifier That Rescues Retinal
Degeneration and Promotes Homeostasis in Multiple Models of Retinitis Pigmentosa."
Gene Therapy 28 (5): 223–41. https://doi.org/10.1038/s41434-020-0134-z.

Maguire, Albert M, Jean Bennett, Elena M Aleman, Bart P Leroy, and Tomas S Aleman.
2021. "Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy."
Molecular Therapy 29 (2): 442–63. https://doi.org/10.1016/j.ymthe.2020.11.029.

Massengill, Michael T, and Alfred S Lewin. 2021. "Gene Therapy for Rhodopsin-
Associated Autosomal Dominant Retinitis Pigmentosa." *International Ophthalmology*
Clinics 61 (4): 79–96. https://doi.org/10.1097/IIO.0000000000000383.

Mitton, K P, P K Swain, S Chen, S Xu, D J Zack, and A Swaroop. 2000. "The Leucine
Zipper of NRL Interacts with the CRX Homeodomain. A Possible Mechanism of
Transcriptional Synergy in Rhodopsin Regulation." *The Journal of Biological*
Chemistry 275 (38): 29794–99. https://doi.org/10.1074/jbc.M003658200.

Moore, Spencer M, Dorota Skowronska-Krawczyk, and Daniel L Chao. 2020. "Targeting
of the NRL Pathway as a Therapeutic Strategy to Treat Retinitis Pigmentosa." *Journal*
of Clinical Medicine 9 (7). https://doi.org/10.3390/jcm9072224.

Murray, Anne R, Steven J Fliesler, and Muayyad R Al-Ubaidi. 2009. "Rhodopsin: The
Functional Significance of Asn-Linked Glycosylation and Other Post-Translational
Modifications." *Ophthalmic Genetics* 30 (3): 109–20.
https://doi.org/10.1080/13816810902962405.

Murray, Anne R, Linda Vuong, Daniel Brobst, Steven J Fliesler, Neal S Peachey,
Marina S Gorbatyuk, Muna I Naash, and Muayyad R Al-Ubaidi. 2015. "Glycosylation

of Rhodopsin Is Necessary for Its Stability and Incorporation into Photoreceptor Outer
Segment Discs." *Human Molecular Genetics* 24 (10): 2709–23.
https://doi.org/10.1093/hmg/ddv031.

Nakamura, Paul A, Andy A Shimchuk, Shibing Tang, Zhizhi Wang, Kole DeGolier,
Sheng Ding, and Thomas A Reh. 2017. "Small Molecule Photoregulin3 Prevents
Retinal Degeneration in the RhoP23H Mouse Model of Retinitis Pigmentosa." *ELife* 6
(November). https://doi.org/10.7554/eLife.30577.

Nakamura, Paul A, Shibing Tang, Andy A Shimchuk, Sheng Ding, and Thomas A Reh.
2016. "Potential of Small Molecule-Mediated Reprogramming of Rod Photoreceptors
to Treat Retinitis Pigmentosa." *Investigative Ophthalmology & Visual Science* 57 (14):
6407–15. https://doi.org/10.1167/iovs.16-20177.

Newton, Fay, and Roly Megaw. 2020. "Mechanisms of Photoreceptor Death in Retinitis
Pigmentosa." *Genes* 11 (10). https://doi.org/10.3390/genes11101120.

O'Neal, Teri B., and Euil E. Luther. 2022. "Retinitis Pigmentosa." In *StatPearls*.
Treasure Island (FL): StatPearls Publishing.

Olsson, J E, J W Gordon, B S Pawlyk, D Roof, A Hayes, R S Molday, S Mukai, G S
Cowley, E L Berson, and T P Dryja. 1992. "Transgenic Mice with a Rhodopsin
Mutation (Pro23His): A Mouse Model of Autosomal Dominant Retinitis Pigmentosa."
Neuron 9 (5): 815–30. https://doi.org/10.1016/0896-6273(92)90236-7.

Parfitt, David A, Amelia Lane, Conor Ramsden, Katarina Jovanovic, Peter J Coffey,
Alison J Hardcastle, and Michael E Cheetham. 2016. "Using Induced Pluripotent
Stem Cells to Understand Retinal Ciliopathy Disease Mechanisms and Develop
Therapies." *Biochemical Society Transactions* 44 (5): 1245–51.
https://doi.org/10.1042/BST20160156.

Perampalam, Pirunthan, and Frederick A Dick. 2020. "BEAVR: A Browser-Based Tool
for the Exploration and Visualization of RNA-Seq Data." *BMC Bioinformatics* 21 (1):
221. https://doi.org/10.1186/s12859-020-03549-8.

"RetNet: Summaries." n.d. Accessed December 24, 2022.
https://web.sph.uth.edu/RetNet/sum-dis.htm.

Sung, Ching-Hwa, and Andrew W. Tai. 1999. "Rhodopsin Trafficking and Its Role in
Retinal Dystrophies." In , 195:215–67. International Review of Cytology. Elsevier.
https://doi.org/10.1016/S0074-7696(08)62706-0.

Sung, C H, C Makino, D Baylor, and J Nathans. 1994. "A Rhodopsin Gene Mutation
Responsible for Autosomal Dominant Retinitis Pigmentosa Results in a Protein That
Is Defective in Localization to the Photoreceptor Outer Segment." *The Journal of*

Neuroscience 14 (10): 5818–33. https://doi.org/10.1523/JNEUROSCI.14-10-
05818.1994.

Tam, Beatrice M, and Orson L Moritz. 2009. "The Role of Rhodopsin Glycosylation in
Protein Folding, Trafficking, and Light-Sensitive Retinal Degeneration." *The Journal of*
Neuroscience 29 (48): 15145–54. https://doi.org/10.1523/JNEUROSCI.4259-09.2009.

Tucker, Budd A, Robert F Mullins, Luan M Streb, Kristin Anfinson, Mari E Eyestone,
Emily Kaalberg, Megan J Riker, Arlene V Drack, Terry A Braun, and Edwin M Stone.
2013. "Patient-Specific IPSC-Derived Photoreceptor Precursor Cells as a Means to
Investigate Retinitis Pigmentosa." *ELife* 2 (August): e00824.
https://doi.org/10.7554/eLife.00824.

Volland, Stefanie, Julian Esteve-Rudd, Juyea Hoo, Claudine Yee, and David S Williams.
2015. "A Comparison of Some Organizational Characteristics of the Mouse Central
Retina and the Human Macula." *Plos One* 10 (4): e0125631.
https://doi.org/10.1371/journal.pone.0125631.

Yamamoto, Haruka, Tetsuo Kon, Yoshihiro Omori, and Takahisa Furukawa. 2020.
"Functional and Evolutionary Diversification of Otx2 and Crx in Vertebrate Retinal
Photoreceptor and Bipolar Cell Development." *Cell Reports* 30 (3): 658-671.e5.
https://doi.org/10.1016/j.celrep.2019.12.072.

Zhao, Linjie, Shengtao Zhou, and Jan-Åke Gustafsson. 2019. "Nuclear Receptors:
Recent Drug Discovery for Cancer Therapies." *Endocrine Reviews* 40 (5): 1207–49.
https://doi.org/10.1210/er.2018-00222.

A

Day timeline:

Embryoid Body | Optic Vesicles | Retinal Organoid | Photoreceptor Outer Segments

Day: 0 — 3:1 — 1 — 1:1 — 2 — 1:3 — 3 — 6 — 7 — 9 — 12 — 15 — 16 — 30 — 120 — 300

iPSC Medium: NIM | NIM | 1.5nM BMP4 | 0.75nM BMP4 | 0.375nM BMP4 | RDM | 3D-RDM + ATRA | 3D-RDM

Suspension Plate (3D) | Matrigel-coated Plate (2D) | Suspension Plate (3D)

D90-D120 — Rods are born

D180-D200 — Outer segments develop

>D250 — Matured rod photoreceptors

B

	D200	D260	D300
RC			OS / ONL
RM			

C

RC — OS, CC, IS

RM — IS

Retinal Organoid-Disease Modeling

No adRP

RHO-CNV- adRP

hiPSCs

Outer Segment

Connecting Cilium

Inner Segment

Cell body

• Proper Rhodopsin localization

Inner Segment

Cell body

• Rhodopsin mislocalization
• Elevated Rhodopsin expression & levels
• Rod degeneration

Small Molecule-Based Therapy

PR3

+

Inner Segment

Cell body

• Rescue of Rhodopsin mRNA levels

• Partial rescue of Rhodopsin from cell body to inner segments

Table 1. Clinical characteristics.

Subject ID (Gender)	Age (~Years)	Age at First Sx (~Years)	VA OD, OS	Slit-Lamp Exam	Dilated Fundus Exam	Genetics
RM (Male)	60s	40s	20/40 20/70-1	Pseudophakic OU	- Mild disc pallor - RPE atrophy adjacent to optic disc and along arcades with RPE hyperplasia - Bone spicules - Mild, non-foveal cystoid macular edema	Chromosome 3q22 duplication rearrangement - Entire RHO gene - 5' regulatory regions - - Flanking genes - 48kb triplicated region embedded within a 188 kb duplication
RC (Female)	30s	N/A	20/20 20/20	OU: Normal	OU: Normal	No Chromosome 3q22 duplication rearrangement

Abbreviations: N/A, not applicable; OD, right eye; OS, left eye; OU, both eyes; RPE, retinal pigmented epithelium; Sx, symptoms; VA, visual acuity.